Die Rationale für Knochenmarkuntersuchungen bei Patienten mit entzündlich-rheumatischen Erkrankungen View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-11

AUTHORS

Jutta G. Richter, Pascal Goßen, Ulrich Germing, Sabine Blum, Barbara Hildebrandt, Stefan Braunstein, Dörte Huscher, Matthias Schneider

ABSTRACT

OBJECTIVE: Inflammatory rheumatic diseases and the applied immunosuppressive treatments can lead to bone marrow depressions and promote hematologic malignancies. Our objective was to explore indications for and results of bone marrow examinations in a large cohort. METHODS: Between 1990 and 2004 146 bone marrow examinations in 3638 patients were performed due to abnormal laboratory results. Medical history, results of bone marrow examination (morphology, histology) and cytogenetic data were investigated retrospectively. RESULTS: Patients' (67.8% female) mean age at bone marrow examination was 53.5 years (SD 15.5), median disease duration 2.9 years. Indications for bone marrow examination were changes in peripheral blood counts in 81.7%. In 52 patients (35.6%) clinically relevant, partially neoplastic bone marrow changes (5 non-Hodgkin lymphoma, 9 myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and 3 myeloproliferative neoplasias) were evident. Medication history showed intake of hydroxy-/chloroquine (13.5%), methotrexate (17.3%), cyclosporin (7.7%), sulfasalazine (7.7%), mycophenolatmofetil, gold, leflunomide (each 1.9%), azathioprine (aza, 25.0%) or cyclophosphamide (cyc, 7.7%) prior to bone marrow examination. 7 out of 9 patients, who developed MDS/AML had been treated with either azathioprine alone or additionally with cyclophosphamide (n = 3). CONCLUSION: One third of our patients showed relevant bone marrow changes that might be associated to therapy. The risk seems to be increased especially in patients with inflammatory rheumatic diseases who had received azathioprine alone or in combination with cyclophosphamide. Health care providers should bear in mind the risk of hematologic malignancies and monitor patients closely in this respect. Bone marrow examination should be performed in case of changes in peripheral blood counts; especially clinically relevant anemia, granulocytes < 2,500/µl, thrombocytes < 100,000/µl and relevant changes over time should lead to bone marrow examinations. More... »

PAGES

690-699

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00508-009-1264-x

DOI

http://dx.doi.org/10.1007/s00508-009-1264-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046553327

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19998010


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Inflammatory Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comorbidity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Germany", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rheumatic Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Klinik f\u00fcr Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Richter", 
        "givenName": "Jutta G.", 
        "id": "sg:person.013132010022.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013132010022.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Klinik f\u00fcr Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Go\u00dfen", 
        "givenName": "Pascal", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr H\u00e4matologie, Onkologie und Klinische Immunologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie und Klinische Immunologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "Ulrich", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr H\u00e4matologie, Onkologie und Klinische Immunologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie und Klinische Immunologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blum", 
        "givenName": "Sabine", 
        "id": "sg:person.01052133152.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052133152.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr Humangenetik und Anthropologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Institut f\u00fcr Humangenetik und Anthropologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hildebrandt", 
        "givenName": "Barbara", 
        "id": "sg:person.01320675564.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr Pathologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Institut f\u00fcr Pathologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Braunstein", 
        "givenName": "Stefan", 
        "id": "sg:person.0746747734.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746747734.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Deutsches Rheuma-Forschungszentrum, Berlin, Germany", 
          "id": "http://www.grid.ac/institutes/grid.418217.9", 
          "name": [
            "Deutsches Rheuma-Forschungszentrum, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huscher", 
        "givenName": "D\u00f6rte", 
        "id": "sg:person.01066535362.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066535362.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Klinik f\u00fcr Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universit\u00e4t D\u00fcsseldorf, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schneider", 
        "givenName": "Matthias", 
        "id": "sg:person.0661644662.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661644662.92"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00508-008-1058-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042879294", 
          "https://doi.org/10.1007/s00508-008-1058-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00296-002-0229-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047743267", 
          "https://doi.org/10.1007/s00296-002-0229-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-006-0532-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052181319", 
          "https://doi.org/10.1007/s10067-006-0532-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00393-006-0105-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018056464", 
          "https://doi.org/10.1007/s00393-006-0105-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1021953224822", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019746259", 
          "https://doi.org/10.1023/a:1021953224822"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncprheum0620", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020115723", 
          "https://doi.org/10.1038/ncprheum0620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-006-0249-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042331470", 
          "https://doi.org/10.1007/s00277-006-0249-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-11", 
    "datePublishedReg": "2009-11-01", 
    "description": "OBJECTIVE: Inflammatory rheumatic diseases and the applied immunosuppressive treatments can lead to bone marrow depressions and promote hematologic malignancies. Our objective was to explore indications for and results of bone marrow examinations in a large cohort. METHODS: Between 1990 and 2004 146 bone marrow examinations in 3638 patients were performed due to abnormal laboratory results. Medical history, results of bone marrow examination (morphology, histology) and cytogenetic data were investigated retrospectively. RESULTS: Patients' (67.8% female) mean age at bone marrow examination was 53.5 years (SD 15.5), median disease duration 2.9 years. Indications for bone marrow examination were changes in peripheral blood counts in 81.7%. In 52 patients (35.6%) clinically relevant, partially neoplastic bone marrow changes (5 non-Hodgkin lymphoma, 9 myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and 3 myeloproliferative neoplasias) were evident. Medication history showed intake of hydroxy-/chloroquine (13.5%), methotrexate (17.3%), cyclosporin (7.7%), sulfasalazine (7.7%), mycophenolatmofetil, gold, leflunomide (each 1.9%), azathioprine (aza, 25.0%) or cyclophosphamide (cyc, 7.7%) prior to bone marrow examination. 7 out of 9 patients, who developed MDS/AML had been treated with either azathioprine alone or additionally with cyclophosphamide (n = 3). CONCLUSION: One third of our patients showed relevant bone marrow changes that might be associated to therapy. The risk seems to be increased especially in patients with inflammatory rheumatic diseases who had received azathioprine alone or in combination with cyclophosphamide. Health care providers should bear in mind the risk of hematologic malignancies and monitor patients closely in this respect. Bone marrow examination should be performed in case of changes in peripheral blood counts; especially clinically relevant anemia, granulocytes < 2,500/\u00b5l, thrombocytes < 100,000/\u00b5l and relevant changes over time should lead to bone marrow examinations.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00508-009-1264-x", 
    "inLanguage": "de", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1070586", 
        "issn": [
          "1026-4906", 
          "1563-2571"
        ], 
        "name": "Wiener klinische Wochenschrift", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "21-22", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "121"
      }
    ], 
    "keywords": [
      "bone marrow examination", 
      "marrow examination", 
      "inflammatory rheumatic diseases", 
      "peripheral blood counts", 
      "bone marrow changes", 
      "rheumatic diseases", 
      "blood count", 
      "hematologic malignancies", 
      "marrow changes", 
      "bone marrow depression", 
      "abnormal laboratory results", 
      "MDS/AML", 
      "health care providers", 
      "relevant anemia", 
      "immunosuppressive treatment", 
      "marrow depression", 
      "medication history", 
      "medical history", 
      "large cohort", 
      "care providers", 
      "patients", 
      "azathioprine", 
      "cyclophosphamide", 
      "malignancy", 
      "examination", 
      "relevant changes", 
      "disease", 
      "laboratory results", 
      "risk", 
      "count", 
      "indications", 
      "cytogenetic data", 
      "Erkrankungen", 
      "sulfasalazine", 
      "anemia", 
      "methotrexate", 
      "therapy", 
      "AML", 
      "cohort", 
      "years", 
      "cyclosporin", 
      "intake", 
      "depression", 
      "thrombocytes", 
      "age", 
      "treatment", 
      "changes", 
      "history", 
      "third", 
      "providers", 
      "cases", 
      "results", 
      "objective", 
      "combination", 
      "case of changes", 
      "data", 
      "time", 
      "mind", 
      "respect", 
      "gold"
    ], 
    "name": "Die Rationale f\u00fcr Knochenmarkuntersuchungen bei Patienten mit entz\u00fcndlich-rheumatischen Erkrankungen", 
    "pagination": "690-699", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046553327"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00508-009-1264-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19998010"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00508-009-1264-x", 
      "https://app.dimensions.ai/details/publication/pub.1046553327"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_476.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00508-009-1264-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00508-009-1264-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00508-009-1264-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00508-009-1264-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00508-009-1264-x'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      22 PREDICATES      107 URIs      92 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00508-009-1264-x schema:about N180d55c536ab43e59ae612541956cae5
2 N2ce3642608964caaa077d909e5decb50
3 N45506361b3974bf89cf6fea6fc018134
4 N5570cb7c9fcc49b39f3aaffa512dc1ba
5 N6c6b9bf3639a46ac8845fa03ddba7eee
6 N78e390d39c4142deb84fbd1f049124a8
7 Nb272048d4bd74b798166d80df8a7ca6a
8 Ndec31285174648b28d9ad42a4871e55b
9 Ne31fbdefbdf14b18bd88fd48ffbed167
10 Ne64767caef6f45c59e177151a50869a8
11 Nea81327358984616b9c7814fae29400d
12 Nf42994a2bdbb4172a31949e8cb31ebba
13 Nf458f166bed148519930bf52825278b3
14 anzsrc-for:11
15 anzsrc-for:1102
16 schema:author N275fa4a1c2fb45c496cc54bdba6b5837
17 schema:citation sg:pub.10.1007/s00277-006-0249-3
18 sg:pub.10.1007/s00296-002-0229-4
19 sg:pub.10.1007/s00393-006-0105-9
20 sg:pub.10.1007/s00508-008-1058-6
21 sg:pub.10.1007/s10067-006-0532-7
22 sg:pub.10.1023/a:1021953224822
23 sg:pub.10.1038/ncprheum0620
24 schema:datePublished 2009-11
25 schema:datePublishedReg 2009-11-01
26 schema:description OBJECTIVE: Inflammatory rheumatic diseases and the applied immunosuppressive treatments can lead to bone marrow depressions and promote hematologic malignancies. Our objective was to explore indications for and results of bone marrow examinations in a large cohort. METHODS: Between 1990 and 2004 146 bone marrow examinations in 3638 patients were performed due to abnormal laboratory results. Medical history, results of bone marrow examination (morphology, histology) and cytogenetic data were investigated retrospectively. RESULTS: Patients' (67.8% female) mean age at bone marrow examination was 53.5 years (SD 15.5), median disease duration 2.9 years. Indications for bone marrow examination were changes in peripheral blood counts in 81.7%. In 52 patients (35.6%) clinically relevant, partially neoplastic bone marrow changes (5 non-Hodgkin lymphoma, 9 myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and 3 myeloproliferative neoplasias) were evident. Medication history showed intake of hydroxy-/chloroquine (13.5%), methotrexate (17.3%), cyclosporin (7.7%), sulfasalazine (7.7%), mycophenolatmofetil, gold, leflunomide (each 1.9%), azathioprine (aza, 25.0%) or cyclophosphamide (cyc, 7.7%) prior to bone marrow examination. 7 out of 9 patients, who developed MDS/AML had been treated with either azathioprine alone or additionally with cyclophosphamide (n = 3). CONCLUSION: One third of our patients showed relevant bone marrow changes that might be associated to therapy. The risk seems to be increased especially in patients with inflammatory rheumatic diseases who had received azathioprine alone or in combination with cyclophosphamide. Health care providers should bear in mind the risk of hematologic malignancies and monitor patients closely in this respect. Bone marrow examination should be performed in case of changes in peripheral blood counts; especially clinically relevant anemia, granulocytes < 2,500/µl, thrombocytes < 100,000/µl and relevant changes over time should lead to bone marrow examinations.
27 schema:genre article
28 schema:inLanguage de
29 schema:isAccessibleForFree false
30 schema:isPartOf N90562588a59646f0bee1f569fb48094b
31 Ne53bbdfa3ce24d109a758d167abd570f
32 sg:journal.1070586
33 schema:keywords AML
34 Erkrankungen
35 MDS/AML
36 abnormal laboratory results
37 age
38 anemia
39 azathioprine
40 blood count
41 bone marrow changes
42 bone marrow depression
43 bone marrow examination
44 care providers
45 case of changes
46 cases
47 changes
48 cohort
49 combination
50 count
51 cyclophosphamide
52 cyclosporin
53 cytogenetic data
54 data
55 depression
56 disease
57 examination
58 gold
59 health care providers
60 hematologic malignancies
61 history
62 immunosuppressive treatment
63 indications
64 inflammatory rheumatic diseases
65 intake
66 laboratory results
67 large cohort
68 malignancy
69 marrow changes
70 marrow depression
71 marrow examination
72 medical history
73 medication history
74 methotrexate
75 mind
76 objective
77 patients
78 peripheral blood counts
79 providers
80 relevant anemia
81 relevant changes
82 respect
83 results
84 rheumatic diseases
85 risk
86 sulfasalazine
87 therapy
88 third
89 thrombocytes
90 time
91 treatment
92 years
93 schema:name Die Rationale für Knochenmarkuntersuchungen bei Patienten mit entzündlich-rheumatischen Erkrankungen
94 schema:pagination 690-699
95 schema:productId N60c6e47e2fa843d5abc5a714a2486554
96 Nbd4f9e90669347b7bc04be76b828ea71
97 Ncb634969ccc64c359e840a1c8b68ef26
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046553327
99 https://doi.org/10.1007/s00508-009-1264-x
100 schema:sdDatePublished 2022-05-20T07:25
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher Nd363adda933b4470a36105c62065ffbd
103 schema:url https://doi.org/10.1007/s00508-009-1264-x
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N180d55c536ab43e59ae612541956cae5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Male
109 rdf:type schema:DefinedTerm
110 N1c98472316ae42cea3d16e931b883d2f schema:affiliation grid-institutes:grid.411327.2
111 schema:familyName Goßen
112 schema:givenName Pascal
113 rdf:type schema:Person
114 N275fa4a1c2fb45c496cc54bdba6b5837 rdf:first sg:person.013132010022.96
115 rdf:rest N3fbc45c97d014764b2e269ee4475186d
116 N2ce3642608964caaa077d909e5decb50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Bone Marrow Diseases
118 rdf:type schema:DefinedTerm
119 N3bde86572cb4429a82a65777088e8cb4 rdf:first sg:person.0746747734.26
120 rdf:rest Nd874b63ab61b469798eb66a315ef7493
121 N3fbc45c97d014764b2e269ee4475186d rdf:first N1c98472316ae42cea3d16e931b883d2f
122 rdf:rest Ndcfd44fb0fbc45bc9d93c1f23a1b8e56
123 N4344b4ea4cc146e292353530ea909c9d rdf:first sg:person.01320675564.15
124 rdf:rest N3bde86572cb4429a82a65777088e8cb4
125 N45506361b3974bf89cf6fea6fc018134 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Germany
127 rdf:type schema:DefinedTerm
128 N5570cb7c9fcc49b39f3aaffa512dc1ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Humans
130 rdf:type schema:DefinedTerm
131 N5f487a04b8ff40c2aca3b7695f3b64de rdf:first sg:person.01052133152.56
132 rdf:rest N4344b4ea4cc146e292353530ea909c9d
133 N60c6e47e2fa843d5abc5a714a2486554 schema:name pubmed_id
134 schema:value 19998010
135 rdf:type schema:PropertyValue
136 N6c6b9bf3639a46ac8845fa03ddba7eee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Comorbidity
138 rdf:type schema:DefinedTerm
139 N78e390d39c4142deb84fbd1f049124a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Risk Assessment
141 rdf:type schema:DefinedTerm
142 N90562588a59646f0bee1f569fb48094b schema:volumeNumber 121
143 rdf:type schema:PublicationVolume
144 Nb272048d4bd74b798166d80df8a7ca6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Rheumatic Diseases
146 rdf:type schema:DefinedTerm
147 Nbd4f9e90669347b7bc04be76b828ea71 schema:name doi
148 schema:value 10.1007/s00508-009-1264-x
149 rdf:type schema:PropertyValue
150 Ncb634969ccc64c359e840a1c8b68ef26 schema:name dimensions_id
151 schema:value pub.1046553327
152 rdf:type schema:PropertyValue
153 Nd363adda933b4470a36105c62065ffbd schema:name Springer Nature - SN SciGraph project
154 rdf:type schema:Organization
155 Nd874b63ab61b469798eb66a315ef7493 rdf:first sg:person.01066535362.41
156 rdf:rest Nda57d9ccf6294838b18c36f07aae6252
157 Nda57d9ccf6294838b18c36f07aae6252 rdf:first sg:person.0661644662.92
158 rdf:rest rdf:nil
159 Ndcfd44fb0fbc45bc9d93c1f23a1b8e56 rdf:first sg:person.01362464041.20
160 rdf:rest N5f487a04b8ff40c2aca3b7695f3b64de
161 Ndec31285174648b28d9ad42a4871e55b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Risk Factors
163 rdf:type schema:DefinedTerm
164 Ne31fbdefbdf14b18bd88fd48ffbed167 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Middle Aged
166 rdf:type schema:DefinedTerm
167 Ne53bbdfa3ce24d109a758d167abd570f schema:issueNumber 21-22
168 rdf:type schema:PublicationIssue
169 Ne64767caef6f45c59e177151a50869a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Incidence
171 rdf:type schema:DefinedTerm
172 Nea81327358984616b9c7814fae29400d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Female
174 rdf:type schema:DefinedTerm
175 Nf42994a2bdbb4172a31949e8cb31ebba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Bone Marrow
177 rdf:type schema:DefinedTerm
178 Nf458f166bed148519930bf52825278b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Anti-Inflammatory Agents
180 rdf:type schema:DefinedTerm
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
185 schema:name Cardiorespiratory Medicine and Haematology
186 rdf:type schema:DefinedTerm
187 sg:journal.1070586 schema:issn 1026-4906
188 1563-2571
189 schema:name Wiener klinische Wochenschrift
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.01052133152.56 schema:affiliation grid-institutes:grid.411327.2
193 schema:familyName Blum
194 schema:givenName Sabine
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052133152.56
196 rdf:type schema:Person
197 sg:person.01066535362.41 schema:affiliation grid-institutes:grid.418217.9
198 schema:familyName Huscher
199 schema:givenName Dörte
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066535362.41
201 rdf:type schema:Person
202 sg:person.013132010022.96 schema:affiliation grid-institutes:grid.411327.2
203 schema:familyName Richter
204 schema:givenName Jutta G.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013132010022.96
206 rdf:type schema:Person
207 sg:person.01320675564.15 schema:affiliation grid-institutes:grid.411327.2
208 schema:familyName Hildebrandt
209 schema:givenName Barbara
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15
211 rdf:type schema:Person
212 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
213 schema:familyName Germing
214 schema:givenName Ulrich
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
216 rdf:type schema:Person
217 sg:person.0661644662.92 schema:affiliation grid-institutes:grid.411327.2
218 schema:familyName Schneider
219 schema:givenName Matthias
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661644662.92
221 rdf:type schema:Person
222 sg:person.0746747734.26 schema:affiliation grid-institutes:grid.411327.2
223 schema:familyName Braunstein
224 schema:givenName Stefan
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746747734.26
226 rdf:type schema:Person
227 sg:pub.10.1007/s00277-006-0249-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042331470
228 https://doi.org/10.1007/s00277-006-0249-3
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s00296-002-0229-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047743267
231 https://doi.org/10.1007/s00296-002-0229-4
232 rdf:type schema:CreativeWork
233 sg:pub.10.1007/s00393-006-0105-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018056464
234 https://doi.org/10.1007/s00393-006-0105-9
235 rdf:type schema:CreativeWork
236 sg:pub.10.1007/s00508-008-1058-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042879294
237 https://doi.org/10.1007/s00508-008-1058-6
238 rdf:type schema:CreativeWork
239 sg:pub.10.1007/s10067-006-0532-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052181319
240 https://doi.org/10.1007/s10067-006-0532-7
241 rdf:type schema:CreativeWork
242 sg:pub.10.1023/a:1021953224822 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019746259
243 https://doi.org/10.1023/a:1021953224822
244 rdf:type schema:CreativeWork
245 sg:pub.10.1038/ncprheum0620 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020115723
246 https://doi.org/10.1038/ncprheum0620
247 rdf:type schema:CreativeWork
248 grid-institutes:grid.411327.2 schema:alternateName Institut für Humangenetik und Anthropologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
249 Institut für Pathologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
250 Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
251 Klinik für Hämatologie, Onkologie und Klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
252 schema:name Institut für Humangenetik und Anthropologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
253 Institut für Pathologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
254 Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
255 Klinik für Hämatologie, Onkologie und Klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
256 rdf:type schema:Organization
257 grid-institutes:grid.418217.9 schema:alternateName Deutsches Rheuma-Forschungszentrum, Berlin, Germany
258 schema:name Deutsches Rheuma-Forschungszentrum, Berlin, Germany
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...